Supplementary Figure 19 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
<p>Supplementary Figure 19. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation. (D) Objective response rate, (E) progression-free survival, and (F)...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Drugi avtorji: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Izdano: |
2025
|
| Teme: | |
| Oznake: |
Označite
Brez oznak, prvi označite!
|